Cannabis May Both Relieve MS Symptoms and Protect Nerve Cells From Damage | Research

The takeaway

Beyond symptom relief, experimental evidence suggests cannabinoids may have neuroprotective properties that could slow multiple sclerosis disease progression.

Read this if you have MS and want to understand whether cannabinoids might do more than just manage symptoms.

Cannabinoids showed both symptom relief and neuroprotective potential in MS models

What the researchers found

The review examined two distinct roles for cannabinoids in MS. First, the established symptom-relief function: cannabis reduces limb spasticity by modulating excessive neuronal signaling, which led to cannabis-based medicines being approved for pain and spasticity in MS.

Second, and more novel, experimental studies revealed that cannabinoids may have neuroprotective effects that could slow disease progression and delay the onset of symptoms like spasticity. This dual potential, treating both symptoms and underlying disease, represented a significant shift in thinking about cannabinoids in MS.

Why it matters

Most MS treatments address either symptoms or disease progression, but rarely both. If cannabinoids can do both simultaneously, they could represent a uniquely valuable class of MS therapeutics. The neuroprotective potential is particularly important because progressive nerve damage is what drives long-term disability in MS.

The numbers in context

Cannabis-based medicines were approved for pain and spasticity in MS at the time of publication. Experimental evidence for neuroprotection came from multiple animal models of MS.

How the study worked

Review of preclinical data from animal models of MS, clinical evidence from human studies, and analysis of the endocannabinoid system biology relevant to MS. Covered both symptom management and neuroprotection research.

What this study cannot tell us

The neuroprotective evidence came primarily from animal models, which do not perfectly replicate human MS. Translating neuroprotective effects from preclinical models to clinical benefit has historically proven very difficult in neurology. Long-term clinical data were lacking.

How to read the evidence

Review combining clinical evidence for symptom relief with preclinical evidence for neuroprotection.

When this study was published

Published in 2012. Research on cannabinoid neuroprotection in MS has continued, though clinical proof of disease modification remains elusive.

The bigger picture

This review shifted the conversation about cannabis and MS from pure symptom management toward disease modification. If cannabinoids can protect nerve cells from the damage that drives MS progression, the clinical implications extend far beyond making patients more comfortable.

Questions still open

Can the neuroprotective effects demonstrated in animal models be replicated in human MS patients? What doses and cannabinoid combinations would be needed for neuroprotection? Could early cannabinoid treatment delay disability progression in MS?

Common questions

Can cannabis slow down MS progression?

Animal studies suggest cannabinoids have neuroprotective properties that could slow nerve damage in MS. However, this has not yet been conclusively demonstrated in human clinical trials. The current approved use of cannabinoid medicines in MS is for symptom relief, particularly spasticity and pain.

How might cannabinoids protect nerve cells?

The endocannabinoid system appears to play a role in regulating inflammation and neuronal survival. Cannabinoids may reduce the excessive immune activity that damages nerve cell myelin in MS, while also directly supporting nerve cell survival through anti-inflammatory and antioxidant mechanisms.

Read the original research

Potential control of multiple sclerosis by cannabis and the endocannabinoid system.

CNS & neurological disorders drug targets, 11(5), 624-41

View on PubMed ↗

Citation

Pryce, Gareth; Baker, David. (2012). Potential control of multiple sclerosis by cannabis and the endocannabinoid system.. CNS & neurological disorders drug targets, 11(5), 624-41.